Diffuse Large B-cell Lymphoma (DLBCL)

Oncology
8
Pipeline Programs
6
Companies
19
Clinical Trials
2 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
3
4
0
0
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Cell Therapy
343%
Monoclonal Antibody
229%
Small Molecule
229%
+ 2 programs with unclassified modality

On Market (1)

Approved therapies currently available

Amgen
RIABNIApproved
rituximab-arrx
Amgen
CD20-directed Cytolytic Antibody [EPC]injection2020

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Amgen
AmgenTHOUSAND OAKS, CA
1 program
1
1
RIABNI(Rituximab)Phase 1/2Monoclonal Antibody5 trials
Active Trials
NCT02747043Completed256Est. Jun 2019
NCT02792699Completed311Est. Oct 2018
NCT02983097Terminated34Est. Apr 2015
+2 more trials
Novartis
NovartisBASEL, Switzerland
4 programs
2
TisagenlecleucelPhase 2Cell Therapy1 trial
TisagenlecleucelPhase 2Cell Therapy1 trial
CAR-TN/ACell Therapy5 trials
KYMRIAHN/A1 trial
Active Trials
NCT05168748Withdrawn0Est. Aug 2026
NCT05172596Terminated146Est. May 2025
NCT05918809Completed1,031Est. Jun 2022
+5 more trials
Genentech
GenentechCA - Oceanside
1 program
1
MosunetuzumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT06828991Recruiting40Est. Apr 2030
BeOne Medicines
BeOne MedicinesCA - San Carlos
1 program
1
ZanubrutinibPhase 2Small Molecule1 trial
Active Trials
NCT05596097Not Yet RecruitingEst. Jul 2026
Philogen
PhilogenItaly - Monteriggioni
1 program
1
L19-IL2 - Ph IPhase 1/21 trial
Active Trials
NCT02957019Terminated6Est. Sep 2023
Ipsen
IpsenChina - Tianjin
1 program
1
TazemetostatPhase 1/2Small Molecule1 trial
Active Trials
NCT02875548Completed58Est. Sep 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
AmgenRituximab
AmgenRituximab
NovartisCAR-T
AmgenRituximab
AmgenRituximab
GenentechMosunetuzumab
BeOne MedicinesZanubrutinib
NovartisCAR-T
NovartisTisagenlecleucel
NovartisTisagenlecleucel
IpsenTazemetostat
PhilogenL19-IL2 - Ph I
AmgenRituximab
NovartisCAR-T
NovartisCAR-T

Showing 15 of 19 trials with date data

Clinical Trials (19)

Total enrollment: 165,471 patients across 19 trials

NCT02747043AmgenRituximab

Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab

Start: May 2016Est. completion: Jun 2019256 patients
Phase 3Completed
NCT02792699AmgenRituximab

Study to Assess if ABP 798 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis (RA) Compared to Rituximab

Start: May 2016Est. completion: Oct 2018311 patients
Phase 3Completed
NCT02445222NovartisCAR-T

CAR-T Long Term Follow Up (LTFU) Study

Start: Nov 2015Est. completion: Feb 20361,400 patients
Phase 3Recruiting
NCT00140595AmgenRituximab

ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients With Diffuse Large B-cell Lymphoma and Age-adjusted IPI of 1

Start: Dec 2003Est. completion: Jan 2009380 patients
Phase 3Completed
NCT00140660AmgenRituximab

ACVBP Versus ACVBP Plus Rituximab in Low Risk Localized Diffuse Large B-cell Lymphoma

Start: Dec 2003Est. completion: Apr 2012223 patients
Phase 3Terminated
NCT06828991GenentechMosunetuzumab

A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP

Start: Sep 2025Est. completion: Apr 203040 patients
Phase 2Recruiting
NCT05596097BeOne MedicinesZanubrutinib

Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial Remission

Start: Oct 2022Est. completion: Jul 2026
Phase 2Not Yet Recruiting
NCT05172596NovartisCAR-T

PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma

Start: Mar 2022Est. completion: May 2025146 patients
Phase 2Terminated
NCT04456023NovartisTisagenlecleucel

Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL)

Start: Jan 2022Est. completion: Sep 20270
Phase 2Withdrawn
NCT02445248NovartisTisagenlecleucel

Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients

Start: Jul 2015Est. completion: Dec 2022115 patients
Phase 2Completed
NCT02875548IpsenTazemetostat

A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study

Start: Aug 2016Est. completion: Sep 202558 patients
Phase 1/2Completed
NCT02957019PhilogenL19-IL2 - Ph I

A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Start: Jul 2013Est. completion: Sep 20236 patients
Phase 1/2Terminated
NCT02983097AmgenRituximab

Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP

Start: Nov 2010Est. completion: Apr 201534 patients
Phase 1/2Terminated
NCT05168748NovartisCAR-T

CD19- and CD22-directed CAR-T Cell Therapy in Patients With Acute Lymphoblastic Leukemia

Start: Jan 2023Est. completion: Aug 20260
Phase 1Withdrawn
NCT04318327NovartisCAR-T

BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma

Start: Jul 2020Est. completion: Apr 202596 patients
Phase 1Terminated
NCT05918809NovartisCAR-T

Real-world Resource Use and Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma (DLBCL): Inpatient and Outpatient Settings

Start: Jul 2021Est. completion: Jun 20221,031 patients
N/ACompleted
NCT05349201NovartisKYMRIAH

CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI)

Start: Dec 2020Est. completion: May 2021273 patients
N/ACompleted
NCT05366257NovartisCAR-T

Real-world Resource Use and Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma (DLBCL)

Start: Aug 2020Est. completion: May 2021160,602 patients
N/ACompleted
NCT00398372AmgenRituximab

Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment

Start: Nov 2000Est. completion: Sep 2009500 patients
N/ACompleted

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
2h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
2h ago

Office Administrator

SystImmune
2h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
3h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
3h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
3h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 165,471 patients
Cell Therapy is the dominant modality (43% of programs)
6 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)